CPX-351
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Molecular Identity
CPX-351
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
PubChem CID: 11422859
2D Structure
Properties
C36H42N4O15
Molecular Formula
770.70
Molecular Weight
g/mol
770.2647
Exact Mass
Da
314
TPSA
May have limited oral absorption
9
H-Bond Donors
16
H-Bond Acceptors
1340
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
CPX-3511256639-86-7RefChem:57344Liposomal Cytarabine-DaunorubicinLiposomal AraC-Daunorubicin CPX-351Daunorubicin and Cytarabine (Liposomal)Liposome-encapsulated Daunorubicin-CytarabineCytarabine-Daunorubicin Liposome for InjectionLiposome-encapsulated Combination of Daunorubicin and CytarabineVyxeos(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-oneVyxeos liposomalCPX 351Cytarabine / daunorubicinDaunorubicin / cytarabine
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to CPX-351
Loading drug network...